
Opinion|Videos|August 21, 2024
Treatment Options in Castration-Resistant Prostate Cancer
Focusing on castration-resistant prostate cancer, the panel reviews treatment options for patients with metastatic and nonmetastatic disease.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
3
Benjamin Lowentritt, MD, reviews real-world testosterone recovery data with relugolix
4
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
5














